Full access to Entrepreneur for $5
Subscribe

Company News for Sep 1, 2021

Companies in the news are: NTES, SONN, EGRX, ZEV

By
This story originally appeared on Zacks
  • NetEase, Inc.’s NTES shares jumped 8.7% after the company reported second-quarter 2021 earnings of 81 cents per share, beating the Zacks Consensus Estimate of 78 cents.
  • Shares of Sonnet BioTherapeutics Holdings, Inc. SONN surged 23.4% after the company announced that its SON-1410 has been selected for melanoma and renal cancers development candidate.
  • Eagle Pharmaceuticals, Inc.’s EGRX shares jumped 10.2% after the company reported it was granted additional patent for Bendamustine Franchise.
  • Shares of Lightning eMotors, Inc. ZEV rose 4.6% after the company and REV Group subsidiary Collins Bus entered into a strategic partnership to manufacture and deploy zero-emission, all-electric Type A school buses.


Infrastructure Stock Boom to Sweep America

- Zacks

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

NetEase, Inc. (NTES): Free Stock Analysis Report

 

Eagle Pharmaceuticals, Inc. (EGRX): Free Stock Analysis Report

 

Sonnet BioTherapeutics Holdings, Inc. (SONN): Free Stock Analysis Report

 

Lightning eMotors, Inc. (ZEV): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research